Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
BIL also holds an option to increase its equity stake by an additional 15%
Physician-led Pi Health has demonstrated capabilities to dramatically reduce clinical trial timelines and administrative burden, while increasing data quality
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Subscribe To Our Newsletter & Stay Updated
